Epizyme, Inc.
Clinical trials sponsored by Epizyme, Inc., explained in plain language.
Biopharmaceutical company developing epigenetic therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
Promising combo for prostate cancer falls short: trial ends early
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with advanced prostate cancer that no longer responds to hormone therapy alone. The goal was to see if the combination could slow cancer growth bet…
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Experimental combo for rare sarcoma shows early promise but trial halted
Disease control TerminatedThis study tested a new drug called tazemetostat combined with standard chemotherapy (doxorubicin) in people with advanced epithelioid sarcoma, a rare soft-tissue cancer. The trial aimed to find a safe dose and see if the combination could help patients live longer without their …
Phase: PHASE1 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Liver impairment study for cancer drug tazemetostat halted early
Knowledge-focused TerminatedThis study looked at how the cancer drug tazemetostat is processed in the body of people with advanced solid tumors who also have moderate or severe liver impairment. Researchers compared drug levels in these patients to those with normal liver function. The trial was terminated …
Phase: PHASE1 • Sponsor: Epizyme, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC